John Coleman
Internal Medicine · Forest, MSNPI 1063945475
Payments from drug & device makers
Across 133 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$604
- Abbott$397
- Novo Nordisk$313
- Lilly USA, LLC$190
- AbbVie$180
- GSK$142
- plus $669 from 16 others
What the payments were for
- Food & beverage$2,39596%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $604 |
| Abbott | 21 | $397 |
| Novo Nordisk | 15 | $313 |
| Lilly USA, LLC | 12 | $190 |
| AbbVie | 11 | $180 |
| GSK | 10 | $142 |
| Astellas Pharma US Inc | 5 | $124 |
| Xeris Pharmaceuticals, Inc. | 3 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Novartis | 5 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Amgen | 3 | $42 |
| OVIK Health, LLC | 1 | $35 |
| Boehringer Ingelheim | 2 | $32 |
| Biogen | 2 | $32 |
| Merck | 2 | $30 |
| Pfizer | 2 | $27 |
| Bayer | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- Ozempic$122
- FREESTYLE LIBRE 3$105
- BREZTRI$100
How this compares
$2,494 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 356 | $228,630 |
| OzempicSemaglutide | 157 | $203,681 |
| FarxigaDapagliflozin Propanediol | 171 | $133,243 |
| JardianceEmpagliflozin | 82 | $86,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $78,468 |
| XareltoRivaroxaban | 163 | $71,044 |
| LinzessLinaclotide | 72 | $66,092 |
| RybelsusSemaglutide | 36 | $55,947 |
| JanuviaSitagliptin Phosphate | 50 | $50,009 |
| CreonLipase/Protease/Amylase | 13 | $39,345 |
| MyrbetriqMirabegron | 51 | $38,111 |
| TrulicityDulaglutide | 23 | $34,688 |
| VraylarCariprazine Hcl | 19 | $28,295 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $26,440 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $24,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $313 | $259,628193 claims |
| PfizerEliquis, Abrysvo | $27 | $237,771385 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $604 | $165,009235 claims |
| AbbVieLinzess, Creon, Vraylar, Combigan | $180 | $139,332127 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $142 | $98,295122 claims |
| Boehringer IngelheimJardiance | $32 | $86,01682 claims |
| MerckJanuvia, Janumet | $30 | $70,49171 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $190 | $51,95137 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $38,11151 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13 | $21,09621 claims |
| NovartisEntresto | $67 | $21,07532 claims |
| BayerKerendia | $18 | $15,15127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Forest
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.